Elisabeth B Stougaard, Peter L Kristensen, Urd Kielgast, Henrik U Andersen, Yasmin Hamid, Peter H Gæde, Esben Søndergaard, Gry H Dørflinger, Karen K Fjeldborg, Klavs W Hansen, Henrik H Thomsen, Thuraya M J Al-Imar, Michael Røder, Vikas S Sridhar, David Cherney, Peter Rossing, Frederik Persson
{"title":"1型糖尿病钠-葡萄糖共转运蛋白2抑制与糖尿病酮症酸中毒风险的现实生活评估","authors":"Elisabeth B Stougaard, Peter L Kristensen, Urd Kielgast, Henrik U Andersen, Yasmin Hamid, Peter H Gæde, Esben Søndergaard, Gry H Dørflinger, Karen K Fjeldborg, Klavs W Hansen, Henrik H Thomsen, Thuraya M J Al-Imar, Michael Røder, Vikas S Sridhar, David Cherney, Peter Rossing, Frederik Persson","doi":"10.1177/14791641221130043","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The indication for treatment of type 1 diabetes(T1D) with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incidence of DKA in people with T1D treated with SGLT2i in Denmark.</p><p><strong>Methods: </strong>Clinical data from adults with T1D in Denmark were collected from nine outpatient clinics. Electronic health records made the search for DKA accurate.</p><p><strong>Results: </strong>From a population of 10.500 we observed 134 people treated with SGLT2i over a total period of 222 patient-years. Of those 72% were female, mean age (SD) was 51.4 (13.6) years and median duration of treatment (median, IQR) with an SGLT2i were 12.0 (6.0-29.0) months. The incidence of DKA was zero%.</p><p><strong>Conclusion: </strong>In 134 people with T1D treated with SGLT2i we found that none of the participants developed DKA during the treatment.</p>","PeriodicalId":11092,"journal":{"name":"Diabetes & Vascular Disease Research","volume":" ","pages":"14791641221130043"},"PeriodicalIF":2.8000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/67/10.1177_14791641221130043.PMC9585567.pdf","citationCount":"2","resultStr":"{\"title\":\"Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis.\",\"authors\":\"Elisabeth B Stougaard, Peter L Kristensen, Urd Kielgast, Henrik U Andersen, Yasmin Hamid, Peter H Gæde, Esben Søndergaard, Gry H Dørflinger, Karen K Fjeldborg, Klavs W Hansen, Henrik H Thomsen, Thuraya M J Al-Imar, Michael Røder, Vikas S Sridhar, David Cherney, Peter Rossing, Frederik Persson\",\"doi\":\"10.1177/14791641221130043\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The indication for treatment of type 1 diabetes(T1D) with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incidence of DKA in people with T1D treated with SGLT2i in Denmark.</p><p><strong>Methods: </strong>Clinical data from adults with T1D in Denmark were collected from nine outpatient clinics. Electronic health records made the search for DKA accurate.</p><p><strong>Results: </strong>From a population of 10.500 we observed 134 people treated with SGLT2i over a total period of 222 patient-years. Of those 72% were female, mean age (SD) was 51.4 (13.6) years and median duration of treatment (median, IQR) with an SGLT2i were 12.0 (6.0-29.0) months. The incidence of DKA was zero%.</p><p><strong>Conclusion: </strong>In 134 people with T1D treated with SGLT2i we found that none of the participants developed DKA during the treatment.</p>\",\"PeriodicalId\":11092,\"journal\":{\"name\":\"Diabetes & Vascular Disease Research\",\"volume\":\" \",\"pages\":\"14791641221130043\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/67/10.1177_14791641221130043.PMC9585567.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes & Vascular Disease Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/14791641221130043\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & Vascular Disease Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/14791641221130043","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis.
Background: The indication for treatment of type 1 diabetes(T1D) with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incidence of DKA in people with T1D treated with SGLT2i in Denmark.
Methods: Clinical data from adults with T1D in Denmark were collected from nine outpatient clinics. Electronic health records made the search for DKA accurate.
Results: From a population of 10.500 we observed 134 people treated with SGLT2i over a total period of 222 patient-years. Of those 72% were female, mean age (SD) was 51.4 (13.6) years and median duration of treatment (median, IQR) with an SGLT2i were 12.0 (6.0-29.0) months. The incidence of DKA was zero%.
Conclusion: In 134 people with T1D treated with SGLT2i we found that none of the participants developed DKA during the treatment.
期刊介绍：
Diabetes & Vascular Disease Research is the first international peer-reviewed journal to unite diabetes and vascular disease in a single title. The journal publishes original papers, research letters and reviews. This journal is a member of the Committee on Publication Ethics (COPE)
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
